Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11965373rdf:typepubmed:Citationlld:pubmed
pubmed-article:11965373lifeskim:mentionsumls-concept:C0043309lld:lifeskim
pubmed-article:11965373lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:11965373lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:11965373lifeskim:mentionsumls-concept:C0179302lld:lifeskim
pubmed-article:11965373lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:11965373lifeskim:mentionsumls-concept:C1880355lld:lifeskim
pubmed-article:11965373pubmed:issue9lld:pubmed
pubmed-article:11965373pubmed:dateCreated2002-4-19lld:pubmed
pubmed-article:11965373pubmed:abstractTextOptimization of the hydrophobic moiety of caprolactam/thiazepinone based compounds led to the identification of potent Src SH2 binders in two different series incorporating a phosphotyrosine group (RU 81843) or a phosphobenzoic group (RU 79181). The X-ray co-structures with the Src SH2 domain revealed different binding modes for RU 81843 and RU 79181, and an excellent fit between RU81843 and the Src SH2 protein thus explaining its high potency (9 nM, 15-fold more potent than pYEEI reference peptide).lld:pubmed
pubmed-article:11965373pubmed:languageenglld:pubmed
pubmed-article:11965373pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11965373pubmed:citationSubsetIMlld:pubmed
pubmed-article:11965373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11965373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11965373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11965373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11965373pubmed:statusMEDLINElld:pubmed
pubmed-article:11965373pubmed:monthMaylld:pubmed
pubmed-article:11965373pubmed:issn0960-894Xlld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:LangeGudrunGlld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:DeprezPierrePlld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:MandineEliane...lld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:VermondAnnieAlld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:LesuisseDomin...lld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:BaholetIsabel...lld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:BurletStéphan...lld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:AmengualRemiRlld:pubmed
pubmed-article:11965373pubmed:authorpubmed-author:SchootBernard...lld:pubmed
pubmed-article:11965373pubmed:issnTypePrintlld:pubmed
pubmed-article:11965373pubmed:day6lld:pubmed
pubmed-article:11965373pubmed:volume12lld:pubmed
pubmed-article:11965373pubmed:ownerNLMlld:pubmed
pubmed-article:11965373pubmed:authorsCompleteYlld:pubmed
pubmed-article:11965373pubmed:pagination1291-4lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:meshHeadingpubmed-meshheading:11965373...lld:pubmed
pubmed-article:11965373pubmed:year2002lld:pubmed
pubmed-article:11965373pubmed:articleTitleDiscovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.lld:pubmed
pubmed-article:11965373pubmed:affiliationAventis Pharma, Paris Research Center, Medicinal Chemistry, 102 route de Noisy, 93235 Cedex, Romainville, France. pierre.deprez@aventis.comlld:pubmed
pubmed-article:11965373pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11965373lld:chembl